IBIO — iBio Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for iBio, fiscal year end - June 30th, USD millions except per share, conversion factor applied.

	C2020 June 30th	2021 June 30th	R2022 June 30th	2023 June 30th	2024 June 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1.64	2.37	1.88	0	0.225
Cost of Revenue
Gross Profit	0.935	0.909	—	—	—
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	15.6	33.5	31.6	29.3	16.9
Operating Profit	-14	-31.1	-29.7	-29.3	-16.6
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-16.4	-23.2	-29.5	-29.3	-15.4
Net Income After Taxes	-16.4	-23.2	-29.5	-29.3	-15.4
Minority Interest
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-16.4	-23.2	-50.3	-65	-24.9
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-38.3	-23.5	-50.4	-65	-24.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-305	-59.6	-63.8	-47	-4.29